About Kyorin Group
Evolution and Innovation II is the basic policy of the Kyorin MIC-09 plan. The name reflects a continuation of Evolution and Innovation, the basic policy of the Kyorin MIC-05 plan, which guided us through the five years prior to March 31, 2006. In line with this basic policy, we will evolve our drug discovery business model and create new businesses to support drug discovery operations.
Under the Kyorin MIC-09 plan, we will establish a global drug discovery organization based around our drug discovery and research institutes in Japan, the United States and Europe.
We intend to build a business model whereby we achieve maximum profit in a short time frame by developing compounds to a late stage and then licensing them out.
We plan to move beyond our traditional domain of ethical drug development, by stepping up efforts to promote innovative health-related businesses that complement our high-risk, high-return drug discovery operations to ensure stable growth.
